Poly (ADP-ribose) polymerase inhibitors (PARPi) in ovarian cancer: lessons learned and future directions | International Journal of Gynecologic Cancer

Subscribe
Log In More

Log in via Institution
Log in via OpenAthens
Log in via your Society

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Current issue

Archive

Authors

About

YouTube

Podcasts

Zoom Journal Club
Subscribe
Log in More

Log in via Institution
Log in via OpenAthens
Log in via your Society

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Article metrics

other Versions

You are currently viewing an earlier version of this article (March 16, 2023).
View the most recent version of this article

Review

Poly (ADP-ribose) polymerase inhibitors (PARPi) in ovarian cancer: lessons learned and future directions

Online download statistics by month:

Online download statistics by month: March 2023 to April 2024

	Abstract	Full	Pdf
Mar 2023	1028	48	47
Apr 2023	1599	1333	500
May 2023	698	635	230
Jun 2023	609	561	212
Jul 2023	305	272	152
Aug 2023	342	315	131
Sep 2023	297	270	114
Oct 2023	315	285	128
Nov 2023	280	247	118
Dec 2023	401	330	90
Jan 2024	283	150	168
Feb 2024	240	157	67
Mar 2024	367	333	132
Apr 2024	171	149	89
Total	6935	5085	2178